Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 1995;26:2048-2052

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaps, M.
Right arrow Articles by Wurst, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaps, M.
Right arrow Articles by Wurst, W.

(Stroke. 1995;26:2048-2052.)
© 1995 American Heart Association, Inc.


Articles

Phase I: Transcranial Echo Contrast Studies in Healthy Volunteers

Manfred Kaps, MD; Peter Schaffer, MD; Klaus-Dieter Beller, MD; Günther Seidel, MD; Harald Bliesath, MD, MSc Wilhelm Wurst, MD, MSc

From the Department of Neurology, University at Lübeck (M.K., G.S.), and Byk Gulden Pharmaceuticals, Clinical Pharmacology, Konstanz (P.S., K.-D.B., H.B., W.W.), Germany.

Correspondence to Prof Dr M. Kaps, Klinik für Neurologie, Universität zu Lübeck, Ratzeburger Allee 160, D-23538 Lübeck, Germany.

Background and Purpose Transcranial ultrasound diagnostics are particularly hindered by insufficient ultrasound penetration through the temporal bone. The use of ultrasonic contrast media to enhance the Doppler signal is an important step toward the solution of this problem. In the present study we investigated the tolerability and the diagnostic value of a new intravenous transpulmonary ultrasonic contrast medium, BY963.

Methods In two phase I studies, 8 healthy volunteers received a spherosome suspension containing a phospholipid as the active ingredient. The intravenous injection was performed in three doses (2.5, 5, and 10 mL) at four different injection rates (0.25, 0.5, and 1 mL/s and bolus). The duration and degree of the signal enhancement were measured by two transcranial ultrasonic procedures presently used in clinical practice: transcranial Doppler sonography (TCD) and transcranial color-coded sonography (TCCS). The assessment of tolerability was based on chemical laboratory parameters and hemodynamic data (heart rate, blood pressure, electrocardiogram) and on questionnaires relating to general well-being.

Results BY963 was tolerated without complications. All 38 administrations of the echo contrast medium produced a marked increase in the TCD signal (>30 dB) in the intracranial basal cerebral arteries. To obtain the optimum time window for diagnostic use, higher doses with slower injection rates are advantageous. The duration of optimal contrasting was 42 to 68 seconds (TCD) and 12 to 132 seconds (TCCS), depending on the method and mode of administration. Bolus injections gave rise to an increased incidence of color artifacts.

Conclusions BY963 significantly improves intracranial Doppler imaging while being well tolerated. The signal enhancement lasts long enough for TCCS to display all basal cerebral arteries after just one injection.


Key Words: cerebrovascular disorders • diagnostic imaging • transcranial Doppler • ultrasonics




This article has been cited by other articles:


Home page
Eur Heart J SupplHome page
G. Deklunder
Role of ultrasound and contrast-enhanced ultrasound in patients with cerebrovascular disease
Eur. Heart J. Suppl., March 1, 2002; 4(suppl_C): C51 - C55.
[Abstract] [PDF]


Home page
StrokeHome page
T. Postert, B. Braun, S. Meves, O. Koster, H. Przuntek, S. Weber, and T. Buttner
Contrast-Enhanced Transcranial Color-Coded Sonography in Acute Hemispheric Brain Infarction
Stroke, September 1, 1999; 30 (9): e1819 - 1826.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
T. Postert, A. Muhs, S. Meves, J. Federlein, H. Przuntek, and T. Buttner
Transient Response Harmonic Imaging : An Ultrasound Technique Related to Brain Perfusion
Stroke, September 1, 1998; 29(9): 1901 - 1907.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
D. G. Nabavi, D. W. Droste, V. Kemeny, G. Schulte-Altedorneburg, S. Weber, and E. B. Ringelstein
Potential and Limitations of Echocontrast-Enhanced Ultrasonography in Acute Stroke Patients : A Pilot Study
Stroke, May 1, 1998; 29(5): 949 - 954.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
T. Postert, J. Federlein, B. Braun, O. Koster, C. Bornke, H. Przuntek, T. Buttner, R. W. Baumgartner, M. Arnold, F. Gonner, et al.
Contrast-Enhanced Transcranial Color-Coded Real-Time Sonography: A Reliable Tool for the Diagnosis of Middle Cerebral Artery Trunk Occlusion in Patients With Insufficient Temporal Bone Window • Response
Stroke, May 1, 1998; 29(5): 1070 - 1073.
[Full Text]


Home page
StrokeHome page
S. Knecht, M. Deppe, A. Ebner, H. Henningsen, T. Huber, H. Jokeit, and E.-B. Ringelstein
Noninvasive Determination of Language Lateralization by Functional Transcranial Doppler Sonography : A Comparison With the Wada Test
Stroke, January 1, 1998; 29(1): 82 - 86.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
R. W. Baumgartner, M. Arnold, F. Gonner, I. Staikow, C. Herrmann, A. Rivoir, and R. M. Muri
Contrast-Enhanced Transcranial Color-Coded Duplex Sonography in Ischemic Cerebrovascular Disease
Stroke, December 1, 1997; 28(12): 2473 - 2478.
[Abstract] [Full Text]


Home page
StrokeHome page
G. Seidel and M. Kaps
Harmonic Imaging of the Vertebrobasilar System
Stroke, August 1, 1997; 28(8): 1610 - 1613.
[Abstract] [Full Text]


Home page
StrokeHome page
M. Kaps, P. Schaffer, K.-D. Beller, K.-D. Eng, G. Seidel, H. Bliesath, E. Diletti, and E. Eng
Characteristics of Transcranial Doppler Signal Enhancement Using a Phospholipid-Containing Echocontrast Agent
Stroke, May 1, 1997; 28(5): 1006 - 1008.
[Abstract] [Full Text]